Welcome to Pharmaxis

Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.

Founded on an Australian discovery, Pharmaxis' products are now available worldwide.

Company Highlights

Major announcement: Positive Bronchitol opinion for Europe

Pharmaxis has announced the CHMP has adopted a positive opinion, recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe.

Bronchitol receives TGA approval for Australians with CF

Pharmaxis has announced that the TGA has approved Bronchitol for marketing in Australia for the treatment of CF .

Results of entitlement offer

On 16 November 2011, Pharmaxis announced an Etitlement Offer to raise approximately $80 million, comprising an institutional component and a retail component. This Entitlement Offer is now fully underwritten.

Phase II allergic asthma trial completes enrolment

Enrolment of all subjects has been completed for the phase II clinical trial evaluating ASM8, a potential new treatment for moderate to severe asthma.